KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Non-Current Deffered Revenue: 2010-2021

Historic Non-Current Deffered Revenue for Pacira BioSciences (PCRX) over the last 8 years, with Dec 2021 value amounting to $10.1 million.

  • Pacira BioSciences' Non-Current Deffered Revenue was N/A to $10.1 million in Q1 2022 from the same period last year, while for Mar 2022 it was $10.1 million, marking a year-over-year change of. This contributed to the annual value of $10.1 million for FY2021, which is N/A change from last year.
  • Pacira BioSciences' Non-Current Deffered Revenue amounted to $10.1 million in FY2021, which was up 35.23% from $7.5 million recorded in FY2016.
  • In the past 5 years, Pacira BioSciences' Non-Current Deffered Revenue registered a high of $10.1 million during FY2021, and its lowest value of $10.1 million during FY2021.
  • In the last 1 years, Pacira BioSciences' Non-Current Deffered Revenue had a median value of $10.1 million in 2021 and averaged $10.1 million.